Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus trastuzumab emtansine versus placebo plus trastuzumab emtansine in adjuvant HER2-positive breast cancer after preoperative therapy
2020-003681-40Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atezolizumab + trastuzumab emtansine with Placebo + trastuzumab emtansine (2 arms). Primary endpoint: Invasive disease-free survival. Started Feb 2021; status: active.
02
Drugs
atezolizumabtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-003681-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003681-40.